PANSS

These are the PANSS subscale and total scale scores of five clinical trial in schizophrenia. A total of \(1941\) patients were treated by \(126\) investiagators (psychiatrists). There were two treatment conditions (risperidone and control). Patients' schizophrenic symptoms were measured using the PANSS (Kay et al., 1988).

In a clinical trial, it frequently occurs that the most credible
outcome to evaluate the effectiveness of a new therapy (the true endpoint) is
difficult to measure. In such a situation, it can be an effective strategy to
replace the true endpoint by a (bio)marker that is easier to measure and that
allows for a prediction of the treatment effect on the true endpoint (a
surrogate endpoint). The package 'Surrogate' allows for an evaluation of the
appropriateness of a candidate surrogate endpoint based on the meta-analytic,
information-theoretic, and causal-inference frameworks. Part of this software
has been developed using funding provided from the European Union's Seventh
Framework Programme for research, technological development and demonstration
(Grant Agreement no 602552), the Special Research Fund (BOF) of Hasselt
University (BOF-number: BOF2OCPO3), GlaxoSmithKline Biologicals, Baekeland
Mandaat (HBC.2022.0145), and Johnson & Johnson Innovative Medicine.

Wim der Elst

Surrogate

Evaluation of Surrogate Endpoints in Clinical Trials

Wim Van Der Elst

Florian Stijven

Fenny Ong

Dries De Witte

Gokce Deliorman

Paul Meyvisch

Alvaro Poveda

Ariel Alonso

Hannah Ensor

Christoper Weir

Geert Molenberghs

PANSS function

A <code>data.frame</code> with \(1941\) observations on \(9\) variables.<dl>
 <dt><code>Pat.Id</code></dt>
<dd>The patient ID.</dd> <dt><code>Treat</code></dt>
<dd>The treatment indicator, coded as \(-1\) = active control and \(1\) = Risperidone.</dd> <dt><code>Invest</code></dt>
<dd>The ID of the investigator (psychiatrist) who treated the patient.</dd> <dt><code>Neg</code></dt>
<dd>The Negative symptoms scale score.</dd> <dt><code>Exc</code></dt>
<dd>The Excitement scale score.</dd> <dt><code>Cog</code></dt>
<dd>The Cognition scale score.</dd> <dt><code>Pos</code></dt>
<dd>The Positive symptoms scale score.</dd> <dt><code>Dep</code></dt>
<dd>The Depression scale score.</dd> <dt><code>Total</code></dt>
<dd>The Total PANSS score.</dd> 
</dl>

Format

PANSS subscales and total score based on the data of five clinical trials in schizophrenia — PANSS

A <code>data.frame</code> with \(1941\) observations on \(9\) variables.<dl>
 <dt><code>Pat.Id</code></dt>
<dd>The patient ID.</dd>

 <dt><code>Treat</code></dt>
<dd>The treatment indicator, coded as \(-1\) = active control and \(1\) = Risperidone.</dd>

 <dt><code>Invest</code></dt>
<dd>The ID of the investigator (psychiatrist) who treated the patient.</dd>

 <dt><code>Neg</code></dt>
<dd>The Negative symptoms scale score.</dd>

 <dt><code>Exc</code></dt>
<dd>The Excitement scale score.</dd>

 <dt><code>Cog</code></dt>
<dd>The Cognition scale score.</dd>

 <dt><code>Pos</code></dt>
<dd>The Positive symptoms scale score.</dd>

 <dt><code>Dep</code></dt>
<dd>The Depression scale score.</dd>

 <dt><code>Total</code></dt>
<dd>The Total PANSS score.</dd>

 
</dl>

PANSS subscales and total score based on the data of five clinical trials in schizophrenia

PANSS: PANSS subscales and total score based on the data of five clinical trials in schizophrenia

Description

Usage

Arguments

Format

References